Darbepoetin-α inhibits the perpetuation of necro-inflammation and delays the progression of cholestatic fibrosis in mice

Laboratory Investigation

Volumn 90, Issue 10, 2010, Pages 1447-1456

  Sigal, Michael ^a   Siebert, Nikolai ^a   Zechner, Dietmar ^a   Menschikow, Elena ^a   Abshagen, Kerstin ^a   Vollmar, Brigitte ^a   Eipel, Christian ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

bile duct ligation; erythropoietin; hypoxia inducible factor; liver; survival

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CHOLESTATIC HEPATITIS; DISEASE COURSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER NECROSIS; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALANINE TRANSAMINASE; ANEMIA; ANIMALS; CHOLESTASIS, EXTRAHEPATIC; COLLAGEN; COMMON BILE DUCT; CYTOPHOTOMETRY; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HEMATINICS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; NECROSIS;

EID: 77957263764     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.115     Document Type: Article

References (37)

1. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J Hepatol 2000;32(1 Suppl):129-140. (Pubitemid 30123630)
2. Hofmann AF. Cholestatic liver disease: pathophysiology and therapeutic options. Liver 2002;22(Suppl 2):14-19.
3. Rodriguez-Garay EA. Cholestasis: human disease and experimental animal models. Ann Hepatol 2003;2:150-158.
4. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305-311. (Pubitemid 14085298)
5. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 2007;6:7. (Pubitemid 47505515)
6. Moon JO, Welch TP, Gonzalez FJ, et al. Reduced liver fibrosis in hypoxia-inducible factor-1{alpha}-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009;296:G582-G592.
7. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002;35:1010-1021. (Pubitemid 34453998)
8. Jeong WI, Do SH, Yun HS, et al. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int 2004;24:658-668.
9. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005;365:1890-1892.
10. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-432.
11. Le Minh K, Klemm K, Abshagen K, et al. Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol 2007;170:1954-1963. (Pubitemid 47339269)
12. Sasu BJ, Hartley C, Schultz H, et al. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol 2005;113:163-174. (Pubitemid 40663266)
13. Georgiev P, Jochum W, Heinrich S, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008;95:646-656.
14. Salguero Palacios R, Roderfeld M, Hemmann S, et al. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest 2008;88:1192-1203.
15. Schmucker DL, Ohta M, Kanai S, et al. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990;12:1216-1221.
16. Imamura M, Ogawa T, Sasaguri Y, et al. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005;128:138-146. (Pubitemid 40039965)
17. Saito JM, Maher JJ. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant. Gastroenterology 2000;118:1157-1168.
18. Gujral JS, Liu J, Farhood A, et al. Reduced oncotic necrosis in Fas receptor-deficient C57BL/6J-lpr mice after bile duct ligation. Hepatology 2004;40:998-1007. (Pubitemid 39288134)
19. Hochhauser E, Pappo O, Ribakovsky E, et al. Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/ reperfusion in an isolated mouse liver model. Apoptosis 2008;13: 77-86.
20. Schmeding M, Hunold G, Ariyakhagorn V, et al. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats. Transpl Int 2009;22:738-746.
21. Shimoda M, Sawada T, Iwasaki Y, et al. Erythropoietin strongly protects the liver from ischemia-reperfusion injury in a pig model. Hepatogastroenterology 2009;56:470-475.
22. Yilmaz S, Ates E, Tokyol C, et al. The protective effect of erythropoietin on ischaemia/reperfusion injury of liver. HPB (Oxford) 2004;6:169-173. (Pubitemid 39248177)
23. Aoshiba K, Onizawa S, Tsuji T, et al. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2009;37:889-898.
24. Bernhardt WM, Eckardt KU. Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Curr Opin Crit Care 2008;14:621-626.
25. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-8685. (Pubitemid 16101107)
26. Gressner AM, Lotfi S, Gressner G, et al. Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J Hepatol 1993;19:117-132. (Pubitemid 23338020)
27. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-1198. (Pubitemid 37314827)
28. Zhang XJ, Ma YX, Wen Y, et al. Erythropoietin suppresses the expressions of TGF-beta1 and collagen in rat cardiac fibroblasts induced by angiotensin II. Zhonghua Xin Xue Guan Bing Za Zhi 2008;36:636-640.
29. Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007;18: 1497-1507.
30. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008;411: 1-18. (Pubitemid 351482341)
31. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol 2009;15:4653-4658.
32. Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010;22:221-227.
33. Tacke F, Schoffski P, Luedde T, et al. Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol 2004;39:259-266. (Pubitemid 38388871)
34. Siciliano M, Tomasello D, Milani A, et al. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995;22(4 Pt 1):1132-1135.
35. Bruno CM, Neri S, Sciacca C, et al. Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol 2004;10:1353-1356. (Pubitemid 39162447)
36. Higgins DF, Kimura K, Iwano M, et al. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008;7:1128-1132. (Pubitemid 351749261)
37. Kimura K, Iwano M, Higgins DF, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008;295:F1023-F1029.